RGD Reference Report - B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice. - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.

Authors: Riccio, L G C  Jeljeli, M  Santulli, P  Chouzenoux, S  Doridot, L  Nicco, C  Reis, F M  Abrão, M S  Chapron, C  Batteux, F 
Citation: Riccio LGC, etal., Hum Reprod. 2019 Jul 8;34(7):1225-1234. doi: 10.1093/humrep/dez071.
RGD ID: 124715471
Pubmed: (View Article at PubMed) PMID:31247078
DOI: Full-text: DOI:10.1093/humrep/dez071

STUDY QUESTION: What are the effects of B lymphocyte inactivation or depletion on the progression of endometriosis?
SUMMARY ANSWER: Skewing activated B cells toward regulatory B cells (Bregs) by Bruton's tyrosine kinase (Btk) inhibition using Ibrutinib prevents endometriosis progression in mice while B cell depletion using an anti-CD20 antibody has no effect.
WHAT IS KNOWN ALREADY: A polyclonal activation of B cells and the presence of anti-endometrial autoantibodies have been described in a large proportion of women with endometriosis though their exact role in the disease mechanisms remains unclear.
STUDY DESIGN, SIZE, DURATION: This study included comparison of endometriosis progression for 21 days in control mice versus animals treated with the anti-CD20 depleting antibody or with the Btk inhibitor Ibrutinib that prevents B cell activation.
PARTICIPANTS/MATERIALS, SETTING, METHODS: After syngeneic endometrial transplantation, murine endometriotic lesions were compared between treated and control mice using volume, weight, ultrasonography, histology and target genes expression in lesions. Phenotyping of activated and regulatory B cells, T lymphocytes and macrophages was performed by flow cytometry on isolated spleen and peritoneal cells. Cytokines were assayed by ELISA.
MAIN RESULTS AND THE ROLE OF CHANCE: Btk inhibitor Ibrutinib prevented lesion growth, reduced mRNA expression of cyclooxygenase-2, alpha smooth muscle actin and type I collagen in the lesions and skewed activated B cells toward Bregs in the spleen and peritoneal cavity of mice with endometriosis. In addition, the number of M2 macrophages decreased in the peritoneal cavity of Ibrutinib-treated mice compared to anti-CD20 and control mice. Depletion of B cells using an anti-CD20 antibody had no effect on activity and growth of endometriotic lesions and neither on the macrophages, compared to control mice.
LIMITATIONS, REASONS FOR CAUTION: It is still unclear whether B cell depletion by the anti-CD20 or inactivation by Ibrutinib can prevent establishment and/or progression of endometriosis in humans.
WIDER IMPLICATIONS OF THE FINDINGS: Further investigation may contribute to clarifying the role of B cell subsets in human endometriosis.
STUDY FUNDING/COMPETING INTEREST(S): This research was supported by a grant of Institut National de la Santé et de la Recherche Médicale and Paris Descartes University. None of the authors has any conflict of interest to disclose.

Disease Annotations    

Objects Annotated

Genes (Rattus norvegicus)
Btk  (Bruton tyrosine kinase)

Genes (Mus musculus)
Btk  (Bruton agammaglobulinemia tyrosine kinase)

Genes (Homo sapiens)
BTK  (Bruton tyrosine kinase)

Additional Information